Comparison

STEMIcathAID vs AngioAID 3D

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

STEMIcathAID

This medical app streamlines STEMI treatment by optimizing patient recognition, response, and record-keeping. It enhances communication and coordination among healthcare providers, reducing critical time to reperfusion for high-risk patients. Features include EKG upload, cardiogenic shock assessment, and live GPS tracking.

Highlights
  • EKG upload via smartphone
  • Cardiogenic shock assessment
  • STEMI patient transfer pathway
  • Live GPS tracking of EMS
  • HIPAA compliant encrypted collaboration
  • Notification system for cath lab preparation
Features
Read full description

STEMIcathAID is a patient recognition, response, and record-keeping system designed to improve outcomes through adherence the American Heart Association’s Mission:Lifeline STEMI guidelines. Early restoration of blood flow to occluded coronary vessels has been shown to significantly improve outcomes for high-risk STEMI patients. STEMIcathAID aims to improve these clinical outcomes by optimizing their treatment following many of the recommendations of the AHA by reducing the time to STEMI recognition, lead acquisition, STEMI identification, notification of the catheterization lab, and reperfusion. There are multiple personnel and steps involved in caring for these high-risk patients. STEMIcathAID takes an algorithmic approach which will enhance the coordination and communication tasks essential to rapid assessment and easy transfer of STEMI patients from the field or outside facility. It will also provide protocols for the EMS or outside hospital provider to identify patients in cardiogenic shock even before their arrival in the catheterization lab. The application will integrate live GPS tracking of the patients alongside the time the alarm was raised prompting the sense of urgency in transferring the patient. Incorporating images, videos, illustrations, and live GPS tracking of the EMS, the design will be subdivided into three main sections: 1. EKG Upload by outside facility or EMS 2. Assessment of Cardiogenic Shock 3. STEMI patient transfer pathway When a medical provider, in the field, other hospital, or outpatient office, suspects STEMI, the provider uploads the EKG by taking a picture of it with their phone. Once the EKG is uploaded, the on-call attending at the PCI-capable facility receives a notification from the application. If the attending believes the patient is experiencing a real STEMI, the pathway is activated. Upon activation, the approximately 10-12 people involved in taking care of the patient are notified so they can begin preparations. Adhering to HIPAA compliance, all users log into the encrypted application and begin to collaborate such aspects as patient vitals, shock information, and emergency vehicle current location and estimated arrival time to the cath lab. Through the optimized communication and collaboration of multiple key players in the STEMI pathway, these time-critical, vulnerable patients can begin treatment promptly.

About

AngioAID 3D

An interactive 3D simulation for learning diagnostic angiography of coronary arteries. Practice advancing catheters, manipulating views, and injecting dye in a realistic environment. Includes review modes with key anatomical and procedural information.

Highlights
  • 3D live simulation of coronary angiography
  • Interactive guidewire and catheter manipulation
  • Hemodynamic monitoring
  • C-Arm angle adjustment
  • Dye injection and cine comparison
  • Review Mode with anatomical insights
  • Tutorial video
Features
Read full description

AngioAID 3D is educational tool designed to teach key concepts of diagnostic angiography of coronary arteries. Developed at the Mount Sinai Hospital in New York City, New York State's highest volume cardiac cath lab, we aim to provide an interactive learning experience on this important topic. Within a 3D live simulation, you begin by advancing a diagnostic guidewire into the aortic root. Then, advance one of many diagnostic catheter options to either the right of left coronary ostium. Through pushing and pulling, as well as rotation of the catheter, try to achieve a truly co-axial engagement of the coronary ostium with the catheter. Meanwhile monitor the hemodynamic tab which simulated damping from over-engagement or roofing of the catheter tip. Line up the view with the target view, zoom to fill the screen with he coronaries, and rotate the C-Arm LAO/RAO and Cranial/Caudal until you're where you think you need to be. Finally, inject dye and take a cine to compare with the one we actually did in the cath lab for this set of coronaries. In addition to the diagnostic simulation, "Review Mode" allows you to play with angles and panning while always being able to see the vessels with no dye injection needed. Also a collection of key topics have been included within the review mode such as key angiographic angles depending on what you're aiming to see clearly, vessel segmentation conventions, and more coronary anatomy and angiography pearls. We highly recommend you view the tutorial video that is available when you first open the application or from the settings page to understand all of the available functions. The first launch has a normal set of coronary arteries but please stay tuned while we create more sets of coronaries such as anomalous coronaries and bypass grafts.

Screenshots

STEMIcathAID4 screens
AngioAID 3D4 screens

Verdict

The call

The clearest difference is rating: AngioAID 3D at 4.0 against STEMIcathAID's 3.3. STEMIcathAID's advantage is ads (none vs shown) and update cadence (every 3 months vs every 28 months). On price, in-app purchases, device support and iOS requirement there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

ReceptionRating · Positive reviews · Number of ratings

AngioAID 3D holds the better App Store score, 4.0 against 3.3. That said, the two scores are not equally well evidenced: STEMIcathAID has 8 ratings behind it against 1, so its average is the more settled of the two.

UpkeepUpdate frequency

STEMIcathAID ships an update every 3 months, AngioAID 3D every 28 months. The most recent releases landed on October 24, 2026 and October 11, 2026 respectively.

Scorecard5 real differences · 4 level
STEMIcathAID versus AngioAID 3D: the parameters behind the verdict, then further details
ParameterSTEMIcathAIDAngioAID 3D
PriceFreeFree
Rating3.3 (8 ratings)4.0 (1 ratings) — better
Number of ratings8 — better1
Update frequencyEvery 3 months — betterEvery 28 months
AdsNo — betterYes
In-app purchasesNoNo
MonetizationFree — betterAd-supported
DevicesiPhone, iPad, iPodiPhone, iPad, iPod
Requires iOS15.115.0 — better
Further details — not scored
Size71 MB92 MB
Age rating4+17+
DeveloperIcahn School of Medicine at Mount SinaiCardiology Apps LLC

Customer experience

STEMIcathAID

All ratings8 ratings
Positive50.0%
Neutral12.5%
Negative37.5%

AngioAID 3D

All ratings1 ratings
Positive100.0%
Neutral0.0%
Negative0.0%

In-app purchases

None

STEMIcathAID

No in-app purchases

None

AngioAID 3D

No in-app purchases

Questions

Is STEMIcathAID free?
STEMIcathAID is free to download, with no in-app purchases.
Is AngioAID 3D free?
AngioAID 3D is free to download, with no in-app purchases.
Which has better reviews, STEMIcathAID or AngioAID 3D?
AngioAID 3D is rated higher. STEMIcathAID averages 3.3 out of 5 from 8 ratings, while AngioAID 3D averages 4.0 from 1 ratings.
Do STEMIcathAID or AngioAID 3D have ads?
AngioAID 3D shows ads; STEMIcathAID does not.
Which is updated more often, STEMIcathAID or AngioAID 3D?
STEMIcathAID ships an update every 3 months, and AngioAID 3D every 28 months. Most recently, STEMIcathAID was updated on October 24, 2026 and AngioAID 3D on October 11, 2026.

Other comparisons